Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial ☆

Annals of Vascular Surgery · Elsevier

Аннотация

Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): L. Xie, W. Yao, Y. Hua, W. Luo, C. Tu, J. Wang, J. Chen, B. Li, D. Zhu, X. Li, Y. Xiao, J. Ma, H. Hu, M. Fang, Z. Huang, H. Wang, Q. Liu, Y. Jin, X. Zhang, X. Niu

Читать у издателя →

Похожие статьи